查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1858138

依给药途径、适应症、药物类型、剂型和患者年龄层分類的皮质类固醇治疗市场－2025-2032年全球预测

Corticosteroids Therapy Market by Route Of Administration, Indication, Drug Type, Dosage Form, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，皮质类固醇治疗市场将成长至 97.3 亿美元，复合年增长率为 7.99%。

关键市场统计数据
基准年 2024 52.6亿美元
预计年份：2025年 56.9亿美元
预测年份 2032 97.3亿美元
复合年增长率 (%) 7.99%

本文简明扼要地总结了重新定义皮质类固醇疗法的临床、商业性和监管因素，并为产业相关人员的策略决策提供指导。

皮质类固醇在多个治疗领域仍是基石，了解其不断变化的临床、商业性和监管环境对于策略决策至关重要。本执行摘要了影响皮质类固醇治疗的当代动态，重点阐述了给药方式、治疗适应症、产品系列、人口结构变化和地缘政治影响如何共同塑造临床实践和供应链韧性。

临床实践正在不断发展，以优化皮质类固醇的剂量、给药途径和联合用药策略，从而在最大限度减少副作用的同时，最大限度地提高疗效。製剂科学和给药技术的进步支持了吸入和局部治疗的广泛应用，而已确立的全身性用药在急性期和维持治疗中仍然发挥着重要作用。同时，监管审查和不断变化的药物安全检测警戒要求迫使生产商加大对强有力的安全监测和核准后证据收集的投入。

在商业性，相关人员面临着一个差异化、药品目录定位和供应安全至关重要的局面。支付方和医疗服务提供者都要求提供相对疗效和经济价值的证据，而采购团队也越来越重视原料药采购和生产能力的上游风险。本摘要旨在为产品组合经理、商业负责人和供应链策略家提供切实可行的见解，帮助他们有效应对这一复杂多变的环境。

技术创新、不断完善的指南和供应链现代化如何改变皮质类固醇治疗的临床实践和商业策略

由于技术创新、临床指南的不断改进以及供应链的重组，皮质类固醇药物市场正在发生变化。近期製剂的创新，透过吸入装置和先进的局部製剂，提高了局部给药的效率和安全性，从而拓展了治疗套件。同时，药物动力学和辅料科学的进步，使得更人性化的局部方案成为可能，提高了患者的依从性，并拓宽了治疗选择。

临床指引正日益重视以病人为中心的风险评估，从而针对慢性病和急性病提出更细緻的建议。这一趋势激发了人们对联合治疗和阶梯式治疗策略的兴趣，这些策略旨在维持疾病控制的同时，降低累积全身暴露量。随着相关人员的积极回应，商业模式也在进行调整，将累积疗效和真实世界证据置于短期商业利益之上。

供应链现代化和对区域製造业的投资正在重塑供应商关係和筹资策略。各组织优先考虑供应商透明度、双重采购和库存缓衝，以降低中断风险。同时，数位健康解决方案和远端监测正在加强依从性追踪和上市后监测，为製造商提供与病人参与和价值展示的新管道。总而言之，这些变化正在创造一个更具韧性、以证据主导的市场环境，在这个环境中，治疗方法差异化和供应完整性至关重要。

评估美国关税调整对皮质类固醇供应链、采购动态和製造韧性的策略影响（截至2025年）

美国加征关税和调整贸易政策将对皮质类固醇价值链产生多方面影响，波及下游的筹资策略、生产布局和商业实践。关税有可能增加进口原料药、辅料和成品药的到岸成本，迫使生产商和经销商重新评估其供应商组合和合约条款。为此，许多公司正在权衡近岸外包和本土生产的经济效益，以及建立合规药品製造地带来的营运复杂性。

除了成本之外，关税还会影响供应商的谈判动态和库存计划。采购团队可能会延长前置作业时间，在不同司法管辖区内分散供应商，并增加安全库存以应对政策引起的波动。这些营运调整往往会波及与支付方和医疗服务提供者的价格谈判，迫使製造商在利润率维持和药品目录竞争力之间寻求平衡。此外，与关税、药品分类和合规相关的行政负担也会延长产品上市时间，并使全球供应链同步更加复杂。

政策变化也凸显了垂直整合和策略联盟的重要性。企业可能会寻求长期供应协议、共同投资生产能力或建立区域伙伴关係，以确保关键投入并维持服务的连续性。贸易伙伴之间的监管相容性和关税分类清晰度成为采购决策的关键因素。综上所述，这些动态表明，企业需要积极主动地跨部门应对关税带来的压力，以保障市场进入和商业性生存能力。

跨给药途径、适应症、药物类别、剂型和年龄组进行多方面細項分析，以帮助进行有针对性的开发和商业化。

精细化的市场区隔架构能够清楚展现临床需求、製剂创新与商业策略之间的交集，进而促进目标明确的产品开发与上市规划。给药途径的区分至关重要，因为吸入、注射、口服和局部用药在研发、监管和依从性方面都存在差异。吸入方式又可进一步细分为干粉吸入器、定量吸入器和雾化器平台，而注射液则需要关注肌肉注射、静脉注射和皮下注射的细微差别。口服类固醇，每种剂型都会影响儿童的接受度和剂量准确度。

过敏性鼻炎和气喘需要疗效显着且局部用药效果最佳的吸入和鼻内製剂，而皮肤病则优先考虑安全性良好的外用药物。发炎性肠道疾病和类风湿性关节炎通常需要具有控制释放特性且需进行全面安全监测的全身用药。药物分类突显了Budesonide、Methylprednisolone、氢化可的松、Hydrocortisone和泼尼松等药物之间的竞争动态和临床差异，每种药物都具有不同的药理学特性和耐受性，从而影响处方行为。

按剂型（乳膏剂、注射、混悬剂、锭剂）进行细分，会与给药途径和适应症交叉，从而决定生产复杂性和患者体验。以患者族群（成人、老年人和儿童）进行细分，则凸显了针对不同年龄层的製剂、儿童偏好以及考虑合併症和多重用药的老年给药策略的必要性。整合这些视角，可以实现生命週期管理、临床证据产生和商业性定位的一致性，从而使产品属性与相关人员的需求保持一致。

美洲、中东和非洲以及亚太地区的监管差异、支付方结构和製造地将如何推动差异化的打入市场策略？

区域动态影响临床实践模式、监管预期和供应链设计，因此，市场准入和生命週期管理需要采取细緻入微的方法。在美洲，医疗保健系统展现出私营和公共支付模式，这些模式优先考虑处方集谈判、真实世界疗效和供应可靠性。该地区还强调差异化证据和合约履行，并拥有强大的生产能力和完善的分销网络。欧洲、中东和非洲地区（EMEA）的管理体制和进入途径各不相同。区域中心和本地生产有助于市场进入，但临床指南和报销框架在各个细分市场之间存在显着差异。在这些地区，满足不同临床医生的偏好并适应当地的药物安全检测标准至关重要。

亚太地区是一个充满活力的市场，新兴市场和成熟市场交错分布，监管严格程度和成本敏感度各不相同。快速的都市化以及慢性呼吸系统疾病和皮肤疾病盛行率的上升，催生了对成熟和新型皮质类固醇疗法的需求。在整个亚太地区，跨境供应链风险、监管协调工作以及不断变化的患者期​​望，凸显了灵活的生产布局、可调整的定价模式以及有针对性的证据生成对于支持市场准入和长期应用的重要性。

竞争动态和策略能力如何影响皮质类固醇领域的产品差异化、供应连续性和主导商业化

在竞争激烈的市场环境中，治疗效果、供应可靠性和实证医学证据决定製药业的商业性成败。拥有整合生产网络的传统製药公司凭藉其规模优势和监管经验，维持着涵盖全身和局部类固醇治疗的广泛产品组合。同时，专注于药物研发和生物技术的公司则致力于製剂改进、器械整合以及特定适应症的开发，以安全性和患者便利性为核心，构建差异化的提案主张。

随着支付方要求提供可靠的真实世界证据和疗效数据以证明处方笺报销的合理性，商业团队与临床开发团队之间的合作变得日益重要。策略伙伴关係、共同开发契约和製造外包关係是加速新型给药系统和替代剂型上市并控制资本密集度的常用机制。此外，企业也在药物安全检测、卫生经济学和病患援助计画方面进行投资，以加强产品定位并维持慢性病患者的用药依从性。总而言之，竞争优势源自于将临床差异化与灵活的生产製造和严谨的上市后证据产生结合。

为製造商和相关人员提供切实可行的策略指南，以协调创新、供应链韧性和证据生成，同时管理商业性风险。

产业领导者应采取积极主动的策略，使临床创新与供应链韧性和支付者期望保持一致。优先投资于製剂平台和器械整合，以增强局部给药、减少全身暴露并提高病患依从性。同时，透过多元化采购、签订长期合约和选择性垂直整合，加强与关键原料药和辅料供应商的关係，以降低供应中断风险并确保供应的连续性。

我们将结合务实的真实世界临床试验和随机对照试验，加强证据生成，以捕捉长期安全性、依从性模式和健康经济学结果。我们将利用这些数据，在与支付方和医疗保健系统的谈判中，提出差异化的提案主张。在营运方面，我们将部署先进的需求感知工具和情境规划，以应对贸易政策变化和物流限制。最后，我们将实施严谨的产品组合管理，使治疗重点与未满足的临床需求和人口趋势保持一致，同时寻求策略伙伴关係，以加速新型製剂和给药系统的上市速度。

我们采用透明的三管齐下的研究途径，结合临床医生访谈、监管审查和营运分析，以检验临床和商业领域的见解。

本研究整合了一手和二手资料，旨在从临床、商业和供应链等多个层面全面观点皮质类固醇疗法。一手资料包括对呼吸科、皮肤科和胃肠科的临床医生、采购负责人和法规事务专业人员的结构化访谈，并辅以与生产和品质专家的私人咨询。二级资讯来源包括同行评审文献、监管指南、药典标准以及公开的产品核可和安全通告资讯。

分析方法优先考虑将定性见解与已记录的法律规范进行交叉检验。该方法强调三角验证，即将访谈观察结果与已发布的指南和生产实践进行比对，以确保解释的可靠性。情境分析用于检验贸易政策变化对采购和分销的营运影响，证据综合则着重于将产品属性与临床需求和病患群体特征相匹配。资料管治实践和调查方法的透明度为所有研究结果奠定了基础，以确保其可重复性和对决策者的实际意义。

总结报告强调，临床创新、实证商业化和供应链韧性的整合是未来成功的决定性因素。

皮质类固醇疗法正处于持久临床效用与日益增长的安全性、差异化和供应需求之间的十字路口。製剂和给药技术的进步，以及不断发展的临床管理，为有针对性的创新创造了机会，这些创新既能改善患者疗效，又能满足支付方和医疗服务提供方的优先事项。同时，地缘政治和贸易政策的发展正将供应链考量提升至策略要务的高度，使韧性成为商业规划的核心要素。

因此，决策者应在临床差异化投资与确保上​​游投入和生产连续性的务实措施之间取得平衡。产生能够证明真实世界获益和成本效益的证据，对于处方讨论和长期应用至关重要。总之，能够有效整合临床科学、法规遵循和运作灵活性，从而提供满足患者、临床医生和医疗保健系统需求的皮质类固醇疗法的机构，将会成功。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 标靶吸入性皮质类固醇製剂对重度气喘治疗成本与疗效的影响
  • 新型小分子糖皮质激素调变器旨在减少慢性发炎疾病的全身性副作用
  • 扩大生物类似注射用皮质类固醇的供应，以改善新兴市场的可及性并促进价格竞争
  • 开发基于奈米技术的皮质类固醇药物递送系统，以增强眼部和皮肤的治疗效果
  • 整合数位健康平台，用于远端监测类风湿性关节炎患者生物製剂皮质类固醇治疗的依从性
  • 推广皮质类固醇和免疫调节剂联合治疗异位性皮肤炎，并提高患者依从性
  • 监管改革将加速新型吸入皮质类固醇疗法在儿童气喘患者的核准途径
  • 基因表现分析技术的进步将指导自体自体免疫疾病全身性皮质类固醇治疗方案的个人化给药策略

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依给药途径分類的皮质类固醇治疗市场

  • 吸入
    • 干粉吸入器
    • 定量吸入器
    • 喷雾器
  • 注射
    • 肌肉内注射
    • 静脉注射
    • 皮下
  • 口服
    • 暂停
    • 药片
  • 局部的
    • 奶油
    • 洗剂
    • 软膏

9. 依适应症分類的皮质类固醇治疗市场

  • 过敏性鼻炎
  • 气喘
  • 皮肤病
  • 发炎性肠道疾病
  • 类风湿性关节炎

第十章 依药物类型分類的皮质类固醇治疗市场

  • Budesonide
  • 地塞米松
  • Hydrocortisone
  • Methylprednisolone
  • 强的松

第十一章：以剂型分類的皮质类固醇治疗市场

  • 奶油
  • 注射
  • 暂停
  • 药片

12. 依患者年龄层分類的皮质类固醇治疗市场

  • 成人版
  • 晚年
  • 孩子们

13. 各地区皮质类固醇治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的皮质类固醇治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国皮质类固醇治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Novartis AG
    • Sanofi SA
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd
    • Mylan NV
    • Sandoz International GmbH
Product Code: MRR-C002B1C9976A

The Corticosteroids Therapy Market is projected to grow by USD 9.73 billion at a CAGR of 7.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.26 billion
Estimated Year [2025] USD 5.69 billion
Forecast Year [2032] USD 9.73 billion
CAGR (%) 7.99%

A concise synthesis of clinical, commercial, and regulatory forces redefining corticosteroid therapy and guiding strategic decision-making for industry stakeholders

Corticosteroids remain a foundational pillar across multiple therapeutic areas, and understanding their evolving clinical, commercial, and regulatory context is essential for strategic decision-making. This executive summary synthesizes contemporary dynamics affecting corticosteroid therapy, emphasizing how delivery modalities, therapeutic indications, product portfolios, demographic shifts, and geopolitical influences converge to shape clinical practice and supply chain resilience.

Clinical practice continues to refine corticosteroid use toward precision in dosing, route selection, and combination strategies that optimize efficacy while mitigating adverse effects. Advances in formulation science and delivery technologies have supported expanded usage in inhalation and topical care, while established systemic agents retain importance in acute and maintenance settings. Concurrently, regulatory scrutiny and evolving pharmacovigilance expectations drive manufacturers to invest in robust safety monitoring and post-authorization evidence generation.

Commercially, stakeholders face a landscape where differentiation, formulary positioning, and supply security are primary considerations. Payers and providers demand evidence of comparative benefit and economic value, and procurement teams increasingly assess upstream vulnerabilities in API sourcing and manufacturing capacity. Throughout this summary, emphasis is placed on actionable insights for portfolio managers, commercial leads, and supply chain strategists seeking to navigate this multifaceted environment effectively.

How technological innovation, guideline evolution, and supply chain modernization are jointly transforming clinical practice and commercial strategy for corticosteroid therapies

The corticosteroid landscape is undergoing transformative shifts driven by technological innovation, evolving clinical guidelines, and supply chain realignment. Recent formulation innovations have expanded the therapeutic toolkit, with inhalation devices and refined topical formulations enhancing local delivery and safety margins. At the same time, improvements in pharmacokinetics and excipient science have enabled more patient-friendly dosing regimens that support adherence and broaden treatment windows.

Clinical guidelines are progressively integrating patient-centered risk assessments, resulting in more nuanced recommendations across chronic and acute indications. This trend has stimulated interest in combination therapies and step-down strategies that maintain disease control while reducing cumulative systemic exposure. As stakeholders respond, commercial models are adapting to emphasize long-term outcomes and real-world evidence rather than short-term transactional gains.

Supply chain modernization and regional manufacturing investments are reshaping vendor relationships and procurement strategies. Organizations are prioritizing supplier transparency, dual sourcing, and inventory buffers to mitigate disruption risk. In parallel, digital health solutions and remote monitoring are enhancing adherence tracking and post-marketing surveillance, offering manufacturers new channels for patient engagement and value demonstration. Taken together, these shifts are fostering a more resilient, evidence-driven market environment in which therapeutic differentiation and supply integrity are paramount.

Assessing the strategic repercussions of United States tariff adjustments on corticosteroid supply chains, procurement dynamics, and manufacturing resilience through 2025

The imposition of tariffs and trade policy adjustments in the United States have a multifaceted impact on the corticosteroid value chain, with downstream implications for procurement strategies, manufacturing footprints, and commercial conduct. Tariffs can increase landed costs for imported APIs, excipients, and finished dosage forms, prompting manufacturers and distributors to reassess supplier portfolios and contractual terms. In response, many organizations are weighing the economics of nearshoring or onshoring manufacturing capacity against the operational complexities of establishing compliant pharmaceutical production sites.

Beyond cost considerations, tariffs influence supplier negotiation dynamics and inventory planning. Procurement teams may extend lead times, diversify suppliers across jurisdictions, and increase safety stock to absorb policy-driven volatility. Such operational shifts often cascade into pricing discussions with payers and providers, where manufacturers must balance margin preservation with formulary competitiveness. Additionally, administrative burdens associated with customs, classification, and compliance can lengthen product launch timelines and complicate global supply synchronization.

Policy shifts also elevate the importance of vertical integration and strategic alliances. Companies may pursue long-term supply agreements, co-investments in manufacturing capacity, or regional partnerships to secure critical inputs and maintain continuity of care. Regulatory compatibility across trade partners and clarity on tariff classifications become decisive factors in sourcing decisions. Collectively, these dynamics underscore the need for a proactive, cross-functional response to tariff-driven pressures to safeguard both access and commercial viability.

A multifaceted segmentation analysis connecting routes, indications, drug classes, dosage forms, and age cohorts to inform targeted development and commercialization

A granular segmentation framework illuminates where clinical demand intersects with formulation innovation and commercial strategy, facilitating targeted product development and go-to-market planning. Route of administration distinctions matter because inhalation, injectable, oral, and topical approaches present distinct development, regulatory, and adherence considerations; inhalation modalities further differentiate across dry powder inhaler, metered dose inhaler, and nebulizer platforms, while injectable solutions require attention to intramuscular, intravenous, and subcutaneous delivery nuances. Oral corticosteroids appear in both suspension and tablet formats, each influencing pediatric acceptability and dosing accuracy, whereas topical management leverages creams, lotions, and ointments that vary in absorption and patient preference.

Indication-based segmentation frames therapeutic priorities and evidence requirements; allergic rhinitis and asthma demand robust inhalation and nasal formulations optimized for local efficacy, while dermatological disorders prioritize topical vehicles with favorable safety profiles. Inflammatory bowel disease and rheumatoid arthritis typically necessitate systemic agents with controlled-release characteristics and comprehensive safety monitoring. Drug type segmentation clarifies competitive dynamics and clinical differentiation, with agents such as budesonide, dexamethasone, hydrocortisone, methylprednisolone, and prednisone each carrying distinct pharmacologic profiles and tolerability considerations that influence prescribing behavior.

Dosage form segmentation-cream, injection, suspension, tablet-intersects with route and indication to determine manufacturing complexity and patient experience. Patient age group segmentation, encompassing adult, geriatric, and pediatric cohorts, underscores the need for age-appropriate formulations, palatability for children, and geriatric dosing strategies that account for comorbidities and polypharmacy. Integrating these lenses enables a cohesive approach to lifecycle management, clinical evidence generation, and commercial positioning that aligns product attributes with stakeholder needs.

How regional regulatory diversity, payer structures, and manufacturing footprints drive differentiated market access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape clinical practice patterns, regulatory expectations, and supply chain design, requiring nuanced approaches to market entry and lifecycle management. In the Americas, healthcare systems demonstrate a mix of private and public payer models that prioritize formulary negotiation, real-world outcomes, and supply reliability; this region also hosts significant manufacturing capacity and advanced distribution networks, placing emphasis on differentiated evidence and contract performance. Europe, Middle East & Africa presents heterogeneous regulatory regimes and access pathways, where regional hubs and localized manufacturing can ease market access while clinical guidelines and reimbursement frameworks vary considerably across submarkets. The necessity to address diverse clinician preferences and align with local pharmacovigilance standards is critical in these territories.

Asia-Pacific features a dynamic mix of emerging and mature markets with differing regulatory rigor and cost sensitivities. Rapid urbanization and increasing prevalence of chronic respiratory and dermatologic conditions have created demand for both established and novel corticosteroid therapies, while governments in several jurisdictions are incentivizing local production and technology transfer to reduce import dependence. Across all regions, cross-border supply chain risks, regulatory harmonization efforts, and evolving patient expectations underscore the importance of flexible manufacturing footprints, adaptive pricing models, and targeted evidence generation to support market access and long-term adoption.

Competitive dynamics and strategic capabilities that influence product differentiation, supply continuity, and evidence-driven commercialization in the corticosteroid sector

Industry participants are navigating a competitive environment where therapeutic efficacy, supply reliability, and evidence generation determine commercial success. Established pharmaceutical companies with integrated manufacturing networks leverage scale and regulatory experience to maintain broad portfolios across systemic and local corticosteroid therapies. At the same time, specialized developers and biotech firms concentrate on formulation advances, device integration, and niche indications to carve differentiated value propositions grounded in safety and patient convenience.

Collaboration between commercial teams and clinical development functions is increasingly important, as payers demand robust real-world evidence and outcomes data to justify formulary placement. Strategic partnerships, co-development agreements, and contract manufacturing relationships are common mechanisms to accelerate access to novel delivery systems and alternative dosage forms while managing capital intensity. Additionally, companies are investing in pharmacovigilance, health economics, and patient support programs to reinforce product positioning and sustain adherence in chronic indications. Overall, competitive advantage arises from integrating clinical differentiation with manufacturing agility and rigorous post-market evidence generation.

Practical strategic directives for manufacturers and stakeholders to align innovation, supply resilience, and evidence generation while managing commercial risk

Industry leaders should adopt a proactive strategy that aligns clinical innovation with supply chain resilience and payer expectations. Prioritize investment in formulation platforms and device integration to enhance local delivery, reduce systemic exposure, and improve patient adherence. Simultaneously, strengthen supplier relationships for critical APIs and excipients through multi-sourcing, long-term agreements, and selective vertical integration to mitigate disruption risks and ensure continuity of supply.

Enhance evidence generation by combining randomized trials with pragmatic, real-world studies that capture long-term safety, adherence patterns, and health-economic outcomes. Use these data to support differentiated value propositions in negotiations with payers and healthcare systems. Operationally, implement advanced demand-sensing tools and scenario planning to respond to trade policy shifts and logistical constraints. Lastly, engage in disciplined portfolio management that aligns therapeutic focus with clinical unmet needs and demographic trends, while pursuing strategic partnerships to accelerate time-to-market for novel formulations and delivery systems.

A transparent, triangulated research approach combining clinician interviews, regulatory review, and operational analysis to validate insights across clinical and commercial domains

This research synthesizes primary and secondary evidence to build a comprehensive perspective on corticosteroid therapy across clinical, commercial, and supply chain dimensions. Primary inputs include structured interviews with clinicians across respiratory, dermatology, and gastroenterology specialties, procurement leaders, and regulatory affairs professionals, complemented by closed-door consultations with manufacturing and quality experts. Secondary sources encompass peer-reviewed literature, regulatory guidances, pharmacopoeial standards, and public disclosures related to product approvals and safety communications.

Analytical methods prioritize cross-validation between qualitative insights and documented regulatory frameworks. The approach emphasizes triangulation, where interview-derived observations are tested against published guidance and manufacturing practices to ensure robust interpretation. Scenario analysis is used to examine the operational impact of trade policy shifts on sourcing and distribution, while evidence synthesis focuses on aligning formulation attributes with clinical needs and patient population characteristics. Data governance practices and methodological transparency underpin all findings to ensure reproducibility and practical relevance for decision-makers.

A conclusive synthesis emphasizing the convergence of clinical innovation, evidence-driven commercialization, and supply chain resilience as determinants of future success

Corticosteroid therapy stands at the intersection of enduring clinical utility and accelerating demands for safety, differentiation, and supply security. Progress in formulation and delivery technologies, coupled with evolving clinical stewardship, creates opportunities for targeted innovation that improves patient outcomes while addressing payer and provider priorities. At the same time, geopolitical and trade policy developments have elevated supply chain considerations to a strategic imperative, making resilience a core component of commercial planning.

Decision-makers should therefore balance investments in clinical differentiation with pragmatic initiatives to secure upstream inputs and manufacturing continuity. Evidence generation that articulates real-world benefits and cost implications will be decisive in formulary discussions and long-term adoption. In sum, success will favor organizations that effectively integrate clinical science, regulatory compliance, and operational agility to deliver corticosteroid therapies that meet the needs of patients, clinicians, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of targeted inhaled corticosteroid formulations on severe asthma management costs and outcomes
  • 5.2. Emerging small-molecule glucocorticoid receptor modulators aiming to reduce systemic side effects in chronic inflammatory diseases
  • 5.3. Expansion of biosimilar corticosteroid injectables improving access in emerging markets and driving price competition
  • 5.4. Development of nanotechnology-based corticosteroid drug delivery systems for enhanced ocular and dermal therapy efficacy
  • 5.5. Integration of digital health platforms for remote monitoring of biologic corticosteroid therapy adherence in rheumatoid arthritis
  • 5.6. Growing adoption of combination corticosteroid and immunomodulator therapies for atopic dermatitis with improved patient adherence
  • 5.7. Regulatory changes accelerating approval pathways for novel inhaled corticosteroid therapies targeting pediatric asthma populations
  • 5.8. Advancements in gene expression profiling guiding personalized dosing strategies for systemic corticosteroid regimens in autoimmune conditions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Corticosteroids Therapy Market, by Route Of Administration

  • 8.1. Inhalation
    • 8.1.1. Dry Powder Inhaler
    • 8.1.2. Metered Dose Inhaler
    • 8.1.3. Nebulizer
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Oral
    • 8.3.1. Suspension
    • 8.3.2. Tablet
  • 8.4. Topical
    • 8.4.1. Cream
    • 8.4.2. Lotion
    • 8.4.3. Ointment

9. Corticosteroids Therapy Market, by Indication

  • 9.1. Allergic Rhinitis
  • 9.2. Asthma
  • 9.3. Dermatological Disorders
  • 9.4. Inflammatory Bowel Disease
  • 9.5. Rheumatoid Arthritis

10. Corticosteroids Therapy Market, by Drug Type

  • 10.1. Budesonide
  • 10.2. Dexamethasone
  • 10.3. Hydrocortisone
  • 10.4. Methylprednisolone
  • 10.5. Prednisone

11. Corticosteroids Therapy Market, by Dosage Form

  • 11.1. Cream
  • 11.2. Injection
  • 11.3. Suspension
  • 11.4. Tablet

12. Corticosteroids Therapy Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Corticosteroids Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Corticosteroids Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Corticosteroids Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. AstraZeneca plc
    • 16.3.3. Novartis AG
    • 16.3.4. Sanofi S.A.
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Teva Pharmaceutical Industries Ltd
    • 16.3.8. Sun Pharmaceutical Industries Ltd
    • 16.3.9. Mylan N.V.
    • 16.3.10. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CORTICOSTEROIDS THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY LOTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY OINTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ASTHMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE CORTICOSTEROIDS THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CORTICOSTEROIDS THERAPY MAR